Bilateral vitelliform maculopathy and deferoxamine toxicity

Retina

Volumn 24, Issue 3, 2004, Pages 464-467

  Gonzales, Christine R ^a,b   Lin, Albert P ^b   Engstrom, Robert E ^a,b   Kreiger, Allan E ^a,b  

^a JULES STEIN EYE INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Deferoxamine; Desferal; Toxicity; Vitelliform

Indexed keywords

DEFEROXAMINE;

AGED; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DISEASE COURSE; ELECTRORETINOGRAPHY; FEMALE; HUMAN; MYELODYSPLASIA; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULA VITELLIFORM DEGENERATION; VISUAL ACUITY;

AGED; DEFEROXAMINE; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IRON CHELATING AGENTS; NEURAL TUBE DEFECTS; RETINA; RETINAL DISEASES; VISUAL ACUITY;

EID: 2942672625     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200406000-00024     Document Type: Article

References (6)

1. Haimovici R, D'Amico DJ, Gragoudas ES, Sokol S, for the Deferoxamine Retinopathy Study Group. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmol 2002; 109:164-171.
2. Mehta M, Engstrom RE, Kreiger AE. Deferoxamine-associated retinopathy after subcutaneous injection. Am J Ophthalmol 1994;118:260-264.
3. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmol 1984;91:443-451.
4. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986;314:869-873.
5. Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single "challenge" dose of deferoxamine. Clin Nephrol 1989;31:45-48.
6. Arden GB, Wonke B, Kennedy C, Huehns ER. Ocular changes in patients undergoing long-term desferrioxamine treatment. Br J Ophthalmol 1984;68:873-877.